Anemia Treatment Drugs Market By Type Of Anemia (Iron Deficiency Anemia, Thalassemia, Aplastic Anemia, Hemolytic Anemia, Sickle Cell Anemia, Pernicious Anemia), By Type Of Drug (Supplements, Antibiotics, Immunosuppresants, Bone Marrow Stimulants, Corticosteroids, Gene Therapy, Iron Chelating Agents) - Growth, Future Prospects And Competitive Landscape, 2018 – 2026
Industry Outlook
Anemia treatment drugs market accounted for a market value of US$ 23,155.8 Mn in 2017 and projected to grow at a CAGR of 16.4% during the forecast period from 2018 to 2026. An abnormal decrease in the level of red blood cells, irregular red blood cell morphology, or inadequate concentration of haemoglobin in the blood results in anemia. Anemia is caused also due to numerous nutritional and non-nutritional factors such as infectious disease including malaria, soil-transmitted- helminthiasis, hookworm, and tuberculosis). The World Health Organization (WHO) estimated that globally anemia prevalence averaged 56%, with geographical variations in Europe & Asia the prevalence is in a range from 35% to 75%.
"Sickle cell anemia market expected to grow at a significant rate in the coming years due to presence more than five molecules in clinical trials phase III owned by large pharmaceutical companies"
During the forecast period from 2018 to 2026, sickle cell anemia will grow at an exponential rate due to rising prevalence & awareness related to sickle cell anemia, and expected market entry of monoclonal antibodies and other biological drugs to treat sickle cell anemia efficiently. According to World Health Organization (WHO), it is estimated that 312,000 children will be born worldwide with sickle cell anemia annually. Globally, the greatest burden exists in Sub-Saharan Africa, where 75% of the world sickle cell disease occurs. However, the three major molecules targeting sickle cell anemia in clinical trial phase III are Rivipansel (Pfizer, Inc.), Voxelotor (Global Blood Therapeutics, Inc.) and GBT440 (Global Blood Therapeutics, Inc.). Thus, market approval of these drugs in the near future will assist the overall growth of sickle cell anemia treatment market.
"Asia Pacific expected to be the fastest growing region in the global anemia treatment drugs market with highest prevalence of anemic population, and increasing awareness related to the diagnosis & treatment of anemia"
During the forecast period from 2018 to 2026, Asia Pacific expected to grow significantly due to rising prevalence & awareness related to anemia, initiation of anemia awareness campaigns by government & non-government organizations, and developing economic & healthcare infrastructure. According to the Sickle Cell Disease Coalition (SCDC), in 2016 India set a world record for screening 7.5 million people for SCD in a single day with help of effective awareness campaigns carried out by both government & non-government organizations. The key development observed in Asia Pacific was associated with the improvement in screening, interventions, skilled healthcare providers, and accessibility for medicines. The strong drug pipeline for anemia treatment also considered as one of the key factors expected to assist the growth of Asia Pacific anemia treatment drugs market in the near future.
Historical & Forecast Period
The anemia treatment drugs market analyzed considering current market trends for base year 2017 and based on future trends CAGRs calculated for the forecast period from 2018 to 2026.
Report Scope by Segments
This report on anemia treatment drugs market provides detailed information related to market dynamics such as restraints, drivers, & opportunities along with global trends. The report provides broad summary of the global anemia treatment drugs market by segmenting the market based on anemia type, drug type, and geography. The objective of publishing this in-depth research report is to assist the industry stakeholders in carrying-out strategic decisions and implementation in the anemia treatment drugs market.
| ATTRIBUTE | DETAILS |
|---|---|
| Research Period | 2016-2026 |
| Base Year | 2017 |
| Forecast Period | 2018-2026 |
| Historical Year | 2016 |
| Unit | USD Million |
| Segmentation |
Anemia Type Segment (2016–2026; US$ Mn) |
|
Drug Type Segment (2016–2026; US$ Mn) |
|
|
Geography Segment (2016–2026; US$ Mn) |
This report further describes the major qualitative assessment factors including key market trends, market drivers & restraints, to assist in better understanding of global anemia treatment drugs market. The major players analyzed based on their product offering, market strategies, recent developments, and business strength. The report also provides attractive investment proposition based on the exhaustive geographical research carried out based on PESTEL analysis. Major companies profiled in the report include Pfizer, Inc., Amgen, Inc., Hoffmann-La Roche Ltd., Merck Sharp & Dohme Corp., Novartis AG, Janssen Pharmaceutical, Bayer AG, AMAG Pharmaceuticals, GlaxoSmithKline plc, Akebia Therapeutics, Vifor Pharma Management, Ltd., and FibroGen, Inc. among others.
Key questions answered in this report
- What are anemia treatment drugs and their applications in different types of anemia?
- Which type of anemia is largest segment in global anemia treatment drugs market?
- What are the recent market trends and growth opportunities for the companies operating in anemia treatment industry?
- Which are the most attractive markets geographically for anemia treatment technology?
- What is pipeline analysis and overall future scenario of anemia treatment drugs market?
- What is the competitive landscape of anemia treatment drugs market?
Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted
Chapter 2. Executive Summary
2.1. Global ATD Market Portraiture
2.2. Global ATD Market, by Type of Anemia, 2017 (US$ Mn)
2.3. Global ATD Market, by Type of Drug, 2017 (US$ Mn)
2.4. Global ATD Market, by Geography, 2017 Vs 2026 (Value %)
Chapter 3. Global Anemia Treatment Drugs (ATD) Market: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.2.1. Rising prevalence of anemia and complications related with diseases related to anemia
3.2.2. Increasing awareness related to anemia diagnosis and treatment especially in developing and under developed countries from Asia, Africa & South America
3.3. Challenges
3.3.1. Chronic anemia is treated with bone marrow transplantation or blood transfusion there no drug treatment available in the market
3.4. Opportunities
3.4.1. Strong pipeline with number of promising molecules that will drive the overall ATD market in the near future
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Landscape
3.6.1. Competitive Landscape, by Key Players, 2017
Chapter 4. Global Anemia Treatment Drugs (ATD) Market, by Type of Anemia, 2016 – 2026 (US$ Mn)
4.1. Overview
4.2. Iron deficiency anemia
4.3. Thalassemia
4.4. Aplastic anemia
4.5. Hemolytic anemia
4.6. Sickle cell anemia
4.7. Pernicious anemia
Chapter 5. Global Anemia Treatment Drugs (ATD) Market, by Type of Drug, 2016 – 2026 (US$ Mn)
5.1. Overview
5.2. Supplements
5.3. Antibiotics
5.4. Immunosuppresants
5.5. Bone Marrow Stimulants
5.6. Corticosteroids
5.7. Gene Therapy
5.8. Iron Chelating Agents
5.9. Pipeline Analysis: Global ATD Market
5.9.1. Overview
5.9.2. Phase III Drugs: Market Size Forecast till 2026 (US$ Mn)
5.9.2.1. FG-4592/Roxadustat (FibroGen)
5.9.2.2. Daprodustat/GSK1278863 (GlaxoSmithKline)
5.9.2.3. Molidustat/BAY85-3934 (Bayer)
5.9.2.4. MT-6548 (Mitsubishi Tanabe Pharma Corporation)
5.9.2.5. Rivipansel/GMI-1070 (Pfizer)
5.9.2.6. Luspatercept (Celgene)
5.9.2.7. AG-348 (Agios Pharmaceuticals, Inc.)
5.9.2.8. Sutimlimab (Bioverativ Therapeutics Inc.)
5.9.2.9. V114 (Merck Sharp & Dohme Corp.)
5.9.2.10. LentiGlobin/BB305 (bluebird bio)
5.9.2.11. APL-2 (Apellis Pharmaceuticals, Inc.)
5.9.2.12. ALXN1210 (Alexion Pharmaceuticals)
5.9.2.13. OMS721 (Omeros Corporation)
5.9.3. Phase II (Tabular Representation)
5.9.4. Phase I (Tabular Representation)
Chapter 6. Global Anemia Treatment Drugs (ATD) Market, by Geography, 2016 – 2026 (US$ Mn)
6.1. Overview
6.2. North America ATD Market Analysis, 2016 – 2026
6.2.1. North America ATD Market, by Type of Anemia, 2016–2026 (US$ Mn)
6.2.2. North America ATD Market, by Type of Drug, 2016–2026 (US$ Mn)
6.2.3. North America ATD Market, by Country, 2016 – 2026 (US$ Mn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe ATD Market Analysis, 2016 – 2026
6.3.1. Europe ATD Market, by Type of Anemia, 2016–2026 (US$ Mn)
6.3.2. Europe ATD Market, by Type of Drug, 2016–2026 (US$ Mn)
6.3.3. Europe ATD Market, by Country, 2016 – 2026 (US$ Mn)
6.3.3.1. U.K.
6.3.3.2. Germany
6.3.3.3. Rest of Europe
6.4. Asia Pacific ATD Market Analysis, 2016 – 2026
6.4.1. Asia Pacific ATD Market, by Type of Anemia, 2016–2026 (US$ Mn)
6.4.2. Asia Pacific ATD Market, by Type of Drug, 2016–2026 (US$ Mn)
6.4.3. Asia Pacific ATD Market, by Country, 2016 – 2026 (US$ Mn)
6.4.3.1. Japan
6.4.3.2. China
6.4.3.3. Rest of APAC
6.5. Latin America ATD Market Analysis, 2016 – 2026
6.5.1. Latin America ATD Market, by Type of Anemia, 2016–2026 (US$ Mn)
6.5.2. Latin America ATD Market, by Type of Drug, 2016–2026 (US$ Mn)
6.5.3. Latin America ATD Market, by Country, 2016 – 2026 (US$ Mn)
6.5.3.1. Brazil
6.5.3.2. Mexico
6.5.3.3. Rest of Latin America
6.6. Middle East & Africa (MEA) ATD Market Analysis, 2016 – 2026
6.6.1. Middle East & Africa ATD Market, by Type of Anemia, 2016–2026 (US$ Mn)
6.6.2. Middle East & Africa ATD Market, by Type of Drug, 2016–2026 (US$ Mn)
6.6.3. MEA ATD Market, by Region, 2016 – 2026 (US$ Mn)
6.6.3.1. GCC
6.6.3.2. Rest of MEA
Chapter 7. Company Profiles
7.1. Amgen, Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. Hoffmann-La Roche Ltd.
7.3. Novartis AG
7.4. Pfizer, Inc.
7.5. Janssen Pharmaceuticals, Inc.
7.6. Teva Pharmaceutical Industries, Ltd.
7.7. AMAG Pharmaceuticals
7.8. Rockwell Medical
7.9. Akebia Therapeutics
7.10. Vifor Pharma Management, Ltd.
7.11. FibroGen, Inc.
7.12. GlaxoSmithKline plc
7.13. Bayer AG
7.14. Omeros Corporation
7.15. Merck Sharp & Dohme Corp.
* ATD - Anemia Treatment Drugs
TABLE 1 Global Anemia Treatment Drugs (ATD) Market, by Type of Anemia, 2016 – 2026 (US$ Mn)
TABLE 2 Global ATD Market, by Type of Drug, 2016 – 2026 (US$ Mn)
TABLE 3 North America ATD Market, by Type of Anemia, 2016 – 2026 (US$ Mn)
TABLE 4 North America ATD Market, by Type of Drug, 2016 – 2026 (US$ Mn)
TABLE 5 North America ATD Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 6 Europe ATD Market, by Type of Anemia, 2016 – 2026 (US$ Mn)
TABLE 7 Europe ATD Market, by Type of Drug, 2016 – 2026 (US$ Mn)
TABLE 8 Europe ATD Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 9 Asia Pacific ATD Market, by Type of Anemia, 2016 – 2026 (US$ Mn)
TABLE 10 Asia Pacific ATD Market, by Type of Drug, 2016 – 2026 (US$ Mn)
TABLE 11 Asia Pacific ATD Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 12 Latin America ATD Market, by Type of Anemia, 2016 – 2026 (US$ Mn)
TABLE 13 Latin America ATD Market, by Type of Drug, 2016 – 2026 (US$ Mn)
TABLE 14 Latin America ATD Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 15 Middle East & Africa ATD Market, by Type of Anemia, 2016 – 2026 (US$ Mn)
TABLE 16 Middle East & Africa ATD Market, by Type of Drug, 2016 – 2026 (US$ Mn)
TABLE 17 Middle East And Africa ATD Market, by Region, 2016 – 2026 (US$ Mn)
TABLE 18 Amgen, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 19 Hoffmann-La Roche Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 20 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 21 Pfizer, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 22 Janssen Pharmaceuticals, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 23 Teva Pharmaceutical Industries, Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 24 AMAG Pharmaceuticals : Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 25 Rockwell Medical : Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 26 Akebia Therapeutics : Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 27 Vifor Pharma Management, Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 28 FibroGen, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 29 GlaxoSmithKline plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 30 Bayer AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 31 Omeros Corporation: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 32 Merck Sharp & Dohme Corp. : Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
FIG. 1 Anemia Treatment Drugs (ATD): Market Segmentation
FIG. 2 Global ATD Market Share, by Type of Anemia, 2017 (US$ Mn)
FIG. 3 Global ATD Market Share, by Type of Drug, 2017 (US$ Mn)
FIG. 4 Global ATD Market, by Geography, 2017 Vs 2026 (Value %)
FIG. 5 Attractive Investment Proposition, by Geography, 2017
FIG. 6 Market Competition Landscape, by Key Players, 2017
FIG. 7 Global Iron Deficiency ATD Market, 2016 – 2026 (US$ Mn)
FIG. 8 Global Thalassemia Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 9 Global Aplastic ATD Market, 2016 – 2026 (US$ Mn)
FIG. 10 Global Hemolytic ATD Market, 2016 – 2026 (US$ Mn)
FIG. 11 Global Sickle Cell ATD Market, 2016 – 2026 (US$ Mn)
FIG. 12 Global Pernicious ATD Market, 2016 – 2026 (US$ Mn)
FIG. 13 Global Supplements Market for Anemia Treatment, 2016 – 2026 (US$ Mn)
FIG. 14 Global Antibiotics Market for Anemia Treatment, 2016 – 2026 (US$ Mn)
FIG. 15 Global Immunosuppressant Market for Anemia Treatment, 2016 – 2026 (US$ Mn)
FIG. 16 Global Bone Marrow Stimulants Market for Anemia Treatment, 2016 – 2026 (US$ Mn)
FIG. 17 Global Corticosteroids Market for Anemia Treatment, 2016 – 2026 (US$ Mn)
FIG. 18 Global Gene Therapy Market for Anemia Treatment, 2016 – 2026 (US$ Mn)
FIG. 19 Global Iron Chelating Agents Market for Anemia Treatment, 2016 – 2026 (US$ Mn)
FIG. 20 U.S. ATD Market, 2016 – 2026 (US$ Mn)
FIG. 21 Canada ATD Market, 2016 – 2026 (US$ Mn)
FIG. 22 U.K. ATD Market, 2016 – 2026 (US$ Mn)
FIG. 23 Germany ATD Market, 2016 – 2026 (US$ Mn)
FIG. 24 Rest Of Europe ATD Market, 2016 – 2026 (US$ Mn)
FIG. 25 Japan ATD Market, 2016 – 2026 (US$ Mn)
FIG. 26 China ATD Market, 2016 – 2026 (US$ Mn)
FIG. 27 Rest Of Asia Pacific ATD Market, 2016 – 2026 (US$ Mn)
FIG. 28 Brazil ATD Market, 2016 – 2026 (US$ Mn)
FIG. 29 Mexico ATD Market, 2016 – 2026 (US$ Mn)
FIG. 30 Rest Of Latin America ATD Market, 2016 – 2026 (US$ Mn)
FIG. 31 GCC ATD Market, 2016 – 2026 (US$ Mn)
FIG. 32 Rest Of Middle East And Africa ATD Market, 2016 – 2026 (US$ Mn)
Choose License
Contact Information
: sales@briskinsights.com
: +448081890034 (UK)